Bioporto A/S
CSE:BIOPOR
Intrinsic Value
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. [ Read More ]
The intrinsic value of one BIOPOR stock under the Base Case scenario is 1.47 DKK. Compared to the current market price of 1.628 DKK, Bioporto A/S is Overvalued by 10%.
Valuation Backtest
Bioporto A/S
Run backtest to discover the historical profit from buying and selling BIOPOR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Bioporto A/S
Current Assets | 82.3m |
Cash & Short-Term Investments | 66.4m |
Receivables | 10.4m |
Other Current Assets | 5.5m |
Non-Current Assets | 7.5m |
Long-Term Investments | 2.2m |
PP&E | 2.2m |
Intangibles | 457k |
Other Non-Current Assets | 2.7m |
Current Liabilities | 25.4m |
Accounts Payable | 6.9m |
Other Current Liabilities | 18.5m |
Non-Current Liabilities | 4.3m |
Long-Term Debt | 4.3m |
Earnings Waterfall
Bioporto A/S
Revenue
|
31m
DKK
|
Cost of Revenue
|
-10.8m
DKK
|
Gross Profit
|
20.2m
DKK
|
Operating Expenses
|
-80.3m
DKK
|
Operating Income
|
-60.2m
DKK
|
Other Expenses
|
3.8m
DKK
|
Net Income
|
-56.3m
DKK
|
Free Cash Flow Analysis
Bioporto A/S
BIOPOR Profitability Score
Profitability Due Diligence
Bioporto A/S's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Bioporto A/S's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
BIOPOR Solvency Score
Solvency Due Diligence
Bioporto A/S's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
Bioporto A/S's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIOPOR Price Targets Summary
Bioporto A/S
According to Wall Street analysts, the average 1-year price target for BIOPOR is 5.1 DKK with a low forecast of 5.05 DKK and a high forecast of 5.25 DKK.
Shareholder Return
BIOPOR Price
Bioporto A/S
Average Annual Return | -4.04% |
Standard Deviation of Annual Returns | 45.86% |
Max Drawdown | -86% |
Market Capitalization | 618.1m DKK |
Shares Outstanding | 379 656 992 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
Contact
IPO
Employees
Officers
The intrinsic value of one BIOPOR stock under the Base Case scenario is 1.47 DKK.
Compared to the current market price of 1.628 DKK, Bioporto A/S is Overvalued by 10%.